Endocannabinoids in aqueous humour of patients with or without diabetes by Richardson, Patrick S. et al.
Richardson P, et al. BMJ Open Ophth 2020;5:e000425. doi:10.1136/bmjophth-2019-000425 1
Original research
Endocannabinoids in aqueous humour 
of patients with or without diabetes
Patrick Richardson,1 Catherine Ortori,2 Dave Barrett,2 Saoirse O'Sullivan,1 
Iskandar Idris   1
To cite: Richardson P, 
Ortori C, Barrett D, et al.  
Endocannabinoids in 
aqueous humour of patients 
with or without diabetes. 
BMJ Open Ophthalmology 
2020;5:e000425. doi:10.1136/
bmjophth-2019-000425
Received 11 December 2019
Revised 14 January 2020
Accepted 21 January 2020
1Division of Medical Sciences 
and Graduate Entry Medicine, 
University of Nottingham, Derby, 
UK
2Centre for Analytical 
Bioscience, University of 
Nottingham, Nottingham, UK
Correspondence to
Dr Iskandar Idris;  iskandar. 
idris@ nottingham. ac. uk
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
AbsTrACT
Objective The primary aim was to determine 
endocannabinoid (EC) concentrations of 
2- arachidonoylglycerol (2- AG), oleoylethanolamine (OEA), 
palmitoylethanolamine (PEA) and anandamide (AEA) in 
the aqueous humour of patients, and to investigate any 
differences in gender and diabetic or ocular disease status.
Methods and Analysis Adult participants (age >18 
years) listed for a routine cataract surgery were recruited. 
For patients with diabetes, results from their most recent 
retinopathy grading were recorded. A sample of aqueous 
humour was removed from the anterior chamber of 
the patients and snap- frozen in liquid nitrogen. Levels 
of 2- AG, PEA, OEA and AEA were measured by liquid 
chromatography- tandem mass spectrometry.
results Aqueous humour samples were taken from 93 
patients (female:male=58:35), with a mean age±SD of 
72.7±9.5 years. Following gender- specific analysis, the 
mean aqueous concentration of AEA in female patients 
without diabetes was significantly higher than in female 
patients with diabetes (0.20±0.03 nM vs 0.07±0.02 
nM, p=0.001). Among female patients with diabetes, 
the aqueous concentration of 2- AG was higher in those 
with diabetic retinopathy compared with those with no 
retinopathy (0.30+0.16 nM vs 0.04±0.01 nM, p=0.0025). 
The aqueous level of the sum of EC was higher in those 
with ocular comorbidity (2.49±0.73 vs 1.44±0.17, 
p=0.0002).
Conclusion There were gender, diabetes status and 
comorbidity differences in aqueous humour EC levels. 
Since EC receptors are present in ocular tissues, including 
the retina (neurons, glia and endothelial cells), differential 
levels of ECs in the aqueous humour of patients with and 
without diabetes may provide a novel therapeutic target for 
diabetic retinopathy.
bACkgrOund
Sight- threatening diabetic retinopathy 
(STDR) from non- resolving vitreous haem-
orrhage, tractional retinal detachment and 
diabetic maculopathy is associated with 
retinal capillary occlusion and breakdown of 
the retinal inner blood–retinal barrier.1 It is 
the leading cause of blindness among individ-
uals aged 20–74 years in the UK,2 with nearly 
all patients with type 1 diabetes and >60% 
of patients with type 2 diabetes having some 
form of retinopathy by the first decade of 
diabetes.3 4 Vascular endothelial growth factor 
(VEGF) and other inflammatory mediators 
induced by hyperglycaemia and ischaemia 
are instrumental in developing diabetic 
retinopathy,2 5 6 and intravitreal anti- VEGF 
biologics, steroid implants and retinal laser 
photocoagulation remain the mainstay of 
treatment.7 However, as many patients remain 
visually impaired, further knowledge of novel 
substances or growth factors associated with 
ischaemia- induced angiogenesis is important 
as we seek novel therapeutic strategies to treat 
and prevent STDR.
Endocannabinoids are naturally produced 
chemicals which are known to exhibit 
neuroprotective and anti- inflammatory 
effects in models of central nervous system 
(CNS) and retinal degenerations.8 9 The 
endocannabinoids anandamide (AEA) and 
Key messages
What is already known about this subject?
 ► Components of the endocannabinoid system are 
widely present in the eyes and play a role in the 
endogenous signalling pathway in both the anterior 
and posterior eye.
 ► Their presence in the aqueous humour of patients 
with diabetes compared with patients without dia-
betes and whether its level is associated with active 
neovascularisation in people with diabetic eye dis-
ease are not known.
What are the new findings?
 ► We report different ocular concentrations of selec-
tive endocannabinoids according to diabetes, reti-
nopathy and gender status.
 ► Findings from this study could form a basis to ex-
plore endocannabinoids as a therapeutic target for 
treatment of diabetic eye disease.
How might these results change the focus of 
research or clinical practice?
 ► This study forms the basis for future studies to in-
vestigate the role of endocannabinoid signalling or 
related compounds in the pathogenesis of diabetic 
eye disease.
 ► Studies on endocannabinoids should report on gen-
der, diabetes status and use of cyclo- oxygenase-2 
inhibitors.
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Table 1 Baseline characteristics
All Male Female
Age
Mean (years) 72.7 72.5 72.9
  SD 9.5 8.3 10.2
  n 93 35 58
Comorbidity
  No 72 25 47
  Yes 21 10 11
Diabetes
  No 61 23 38
  Yes 32 12 20
Retinal grade
  R0 23 11 12
  R1 7 1 6
  R2 0 0 0
  R3 2 0 2
  M0 27 12 15
  M1 5 0 5
The table reports the baseline characteristics of the population 
studied grouped according to gender, ocular comorbidities, 
diabetes status and retinopathy grading.
R0 is no retinopathy, R1 is background retinopathy, R2 
preproliferative retinopathy and R3 is proliferative retinopathy. M0 
is no maculopathy and M1 maculopathy.
2- arachidonoylglycerol (2- AG) are found throughout the 
eye, with the exception of the lens,10 and bind to cannabi-
noid 1 receptor (CB
1
) and cannabinoid 2 receptor (CB
2
). 
CB
1
 is expressed in the ciliary body, trabecular meshwork, 
Schlemm’s canal and retina,11 while CB
2
 is present in the 
retina and may contribute to normal visual function.12 
The structurally related compounds N- oleoylethanol-
amine (OEA) and N- palmitoylethanolamine (PEA) are 
also widely distributed in the CNS and periphery, but 
do not have affinity for CB
1
 and CB
2
 receptors and are 
thus termed endocannabinoid- like compounds. They 
are, however, ligands for several non- cannabinoid 
receptor targets of endocannabinoid localised to the eye, 
including peroxisome proliferator- activated receptor,13 
transient receptor potential type vanilloid 1 receptor14, 
the G protein- coupled receptors GPR18, a cannabinoid- 
related receptor that is activated by N- arachidonoyl 
glycine,15 and GRP55 found in rod photoreceptors.12
The presence of these components supports a potential 
role for the ocular endocannabinoid system (ECS) in the 
endogenous signalling of both the anterior and posterior 
segments of the eye. Indeed, endocannabinoid levels have 
been shown to be enhanced in many ocular pathologies, 
including diabetic retinopathy,16 age- related macular 
degeneration16 and glaucoma.17 In diabetic retinopathy, 
tissue 2- AG was increased in the iris, and AEA increased 
in the retina, ciliary body and cornea.16 Similarly, AEA 
was increased in age- related macular degeneration in the 
retina, choroid, ciliary body and cornea.17 No previous 
studies have examined the levels of endocannabinoid in 
the aqueous humour of patients with diabetes compared 
with patients without diabetes, and whether levels are 
associated with STDR. Further, in view of previous studies 
implying that gender and diabetes may affect endo-
cannabinoid concentrations,18–23 we investigated any 
differences of aqueous endocannabinoid concentration 
between gender.
MeTHOds
We conducted a single- centre, cross- sectional pilot 
study to investigate the levels of endocannabinoid and 
endocannabinoid- like compounds in the aqueous 
humour of patients undergoing routine cataract surgery. 
The primary objective was to quantify levels of endo-
cannabinoid (2- AG, AEA, OEA and PEA) and compare 
them in patients with or without diabetes and to look 
for differences in gender. Adult participants (age >18 
years) were recruited from Royal Derby Hospital cataract 
clinics. For patients with diabetes, results from their most 
recent diabetic retinopathy grading were recorded and 
graded according to the English Diabetic Eye Screening 
Criteria: no retinopathy (R0), background retinopathy 
(R1), preproliferative retinopathy (R2), proliferative 
retinopathy (R3) and maculopathy (M1). Patients with 
diabetic maculopathy, preproliferative or stable treated 
proliferative diabetic retinopathy were commenced on 
nepafenac drops, a non- steroid anti- inflammatory drug, 
on the day prior to surgery to reduce the risk of pseu-
dophakic macular oedema. Aqueous humour samples 
were obtained through a paracentesis at the start of the 
operation using a 27 Rycroft cannula on a 1 mL syringe 
(BD), decanted into a labelled 1.0 mL CryoPure vial 
(Sarstedt), snap- frozen in liquid nitrogen and stored in 
a −80°C freezer prior to analysis. Labelling was anony-
mised in accordance with the Human Tissue Authority 
guidance. No adverse events were reported from the 
procedure.
Laboratory analysis
The extraction, purification and quantification of endo-
cannabinoids from ocular fluid were performed using 
a method modified from an established procedure for 
analysis of endocannabinoids in plasma and mamma-
lian tissues.18–22 Internal standards 30 µL of 2- AG- d8 
(5 µM) and 15 µL of AEA- d8 (28 µM) were added to 
each sample prior to extraction. The analytical Liquid 
chromatography- mass spectrometrymass spectrometry 
(LC- MS/MS) method used was not an isotope dilution 
method and hence does not require an isotopically 
labelled internal standard for each analyte. Since the 
chemical structures of AEA, OEA and PEA are very 
similar, the use of the single internal standard (AEA) is 
justified. Ethyl acetate:hexane (650 L 9:1 v/v) was added 
to each sample and vortexed for 10 min. Samples were 
then centrifuged (13 000 rpm, 10 min, 4°C). The upper 
organic layer was removed, and where present the 
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Table 2 Aqueous endocannabinoid levels
2- AG AEA OEA PEA Sum
All Mean 0.07 0.11 0.16 0.92 1.13
  SEM 0.01 0.01 0.02 0.08 0.11
Female Mean 0.06 0.13 0.18 1.11 1.65
  SEM 0.02 0.02 0.02 0.11 0.18
Male Mean 0.10 0.09 0.13 0.63 1.00
  SEM 0.02 0.02 0.02 0.09 0.15
Without diabetes Mean 0.05 0.13 0.17 0.96 1.29
  SEM 0.01 0.02 0.02 1.10 0.23
With diabetes Mean 0.08 0.07 0.14 0.85 1.35
  SEM 0.02 0.02 0.03 0.11 0.23
Women without diabetes Mean 0.05 0.20 0.29 1.22 2.04
  SEM 0.02 0.03 0.04 0.14 0.28
Women with diabetes Mean 0.08 0.07 0.14 0.83 1.34
  SEM 0.03 0.02 0.03 0.14 0.30
Men without diabetes Mean 0.04 0.09 0.13 0.52 0.85
  SEM 0.01 0.02 0.02 0.10 0.14
Men with diabetes Mean 0.12 0.13 0.21 0.89 1.35
  SEM 0.05 0.06 0.08 0.20 0.35
No ocular comorbidity Mean 0.15 0.16 0.22 0.94 1.44
  SEM 0.03 0.03 0.03 0.11 0.17
Ocular comorbidity Mean 0.34 0.35 0.43 1.36 2.49
  SEM 0.14 0.11 0.16 0.34 0.73
The table reports the mean concentration (nM) and SEM of specific endocannabinoids found in the aqueous humour of patients with 
cataract. Patients are grouped by gender, diabetic status and presence of ocular comorbidity.
AEA, anandamide; 2- AG, 2- arachidonoylglycerol; OEA, oleoylethanolamine; PEA, palmitoylethanolamine.
extraction of the aqueous layer was repeated, pooling 
the supernatants for drying. Samples were reconsti-
tuted in 50 µL acetonitrile by vigorous vortexing, and 
endocannabinoids were quantified against a series of 
extracted standards. A modular Exion LC series (Sciex, 
Warrington, UK) ultra High Performance Liquid Chro-
matography (uHPLC) system with a Waters UPLC BEH 
C18 1.7 µm (2.1×150 mm) column held at 60°C was used 
with an injection volume of 5 µL and a gradient elution 
flow rate of 0.45 mL/min. Mobile phase A was water with 
1 g/L ammonium acetate and 0.1% formic acid, and 
mobile phase B was acetonitrile with 1 g/L ammonium 
acetate and 0.1% formic acid premixed in 10% water. 
The QTRAP 6500+ mass spectrometer (Sciex) was used 
with positive ion electrospray detection in multiple reac-
tion monitoring (MRM) mode. Precursor and product 
ions monitored were as follows: 2- AG (379.1/287.2), 
AEA (348.1/62.0), OEA (326.2/62.0), PEA (300.2/62.0), 
2- AG- d8 (387.2/294.2) and AEA- d8 (356.2/63.1).
Patient involvement
Patients or the public were not involved in the design, 
conduct, reporting or dissemination plans of our 
research.
statistical analysis
Normality assumption was tested and rejected using 
the D’Agostino- Pearson omnibus test and outliers were 
detected. We therefore compared endocannabinoid 
levels between treatment groups using Mann- Whitney 
‘t’-test or one- way analysis of variance, and differences 
between groups were considered to be significant at 
p<0.05 after correcting for multiple comparisons. Statis-
tical analyses were performed with GraphPad Prism V.8.3 
(GraphPad Software, San Diego, California).
resuLTs
Aqueous humour samples were taken from 93 patients 
(female:male=58:35), with a mean age±SD of 72.7±9.5 
years (table 1), of whom 32 had diabetes (female:-
male=20:12). Ocular comorbidity was present in 19 
patients (8 macular degeneration, 5 glaucoma, 2 iritis, 
2 retinal vein occlusions, 2 treated retinal detachments). 
All four endocannabinoids were identified in the aqueous 
humour samples, and the mean concentration±SEM 
(nM) of AEA, 2- AG, OEA and PEA were 0.11±0.01, 
0.07±0.01, 0.16±0.02 and 0.92±0.08, respectively, after 
adjusting for statistical outliers. Table 2 describes the 
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Figure 1 Ocular concentration of endocannabinoids 
(AEA (A), PEA (B), OEA (C) and 2- AG (D)) in male and 
female patients. Data are presented as scatterplots and 
analysed by Mann- Whitney non- parametric analysis. 2- 
AG, 2- arachidonoylglycerol; AEA, anandamide; OEA, 
oleoylethanolamine; PEA, palmitoylethanolamine. (*) 
Significant value
Figure 2 Ocular concentration of endocannabinoids 
(AEA (A), PEA (B), OEA (C) and 2- AG (D)) with and 
without diabetes. Data are presented as scatterplots and 
analysed by Mann- Whitney non- parametric analysis. 2- 
AG, 2- arachidonoylglycerol; AEA, anandamide; OEA, 
oleoylethanolamine; PEA, palmitoylethanolamine.
Figure 3 Ocular concentration of endocannabinoids (AEA, 
PEA, OEA and 2- AG) according to ocular comorbidity. 
2- AG, 2- arachidonoylglycerol; AEA, anandamide; OEA, 
oleoylethanolamine; PEA, palmitoylethanolamine.
endocannabinoid levels according to diabetes, gender 
and ocular comorbidity status.
The sum of all endocannabinoids was significantly 
higher in women than in men (1.77±0.20 nM vs 
1.00±0.15 nM, p=0.0298), which was largely driven by the 
significantly higher levels of PEA in women compared 
with men (1.1±0.10 nM vs 0.63±0.09 nM, p=0.0171) 
(figure 1A- D).
When comparing patients with or without diabetes, 
aqueous concentrations of AEA were non- significantly 
lower in those with diabetes compared with those without 
diabetes (0.07±0.02 nM vs 0.13±0.02 nM, p=0.098) 
(figure 2A), while the mean concentration of 2- AG 
was non- significantly higher in patients with diabetes 
compared with those without diabetes (0.08±0.02 nM vs 
0.05±0.01 nM, p=0.067) (figure 2D). The mean aqueous 
concentrations of PEA and OEA were similar between 
patients with and without diabetes (figure 2B,C). 
Comparisons between patients with and without ocular 
comorbidity showed a similar trend, with concentrations 
of 2- AG observed to be non- significantly higher in patients 
with ocular comorbidity (0.17±0.03 nM vs 0.25±0.14 nM, 
p=0.067) and concentrations of AEA shown to be non- 
significantly higher in patients with ocular comorbidity 
(0.13±0.03 nM vs 0.07±0.11 nM, p=0.0853) (figure 3). 
The aqueous level of the sum of endocannabinoids was 
higher in those with ocular comorbidity (2.49±0.73 vs 
1.44±0.17, p=0.0002) (table 2).
Following gender- specific analysis, the aqueous 
concentration of AEA in women was significantly lower 
in patients with diabetes compared with patients without 
diabetes (0.07±0.02 nM vs 0.20±0.03 nM, p<0.001) 
(figure 4), and the mean aqueous PEA in women without 
diabetes was significantly higher than in men without 
diabetes (1.22±0.14 nM vs 0.83±0.14 nM, p=0.0001). 
Among women with diabetes, the aqueous concentration 
of 2- AG was higher in those with diabetic retinopathy 
compared with those with no retinopathy (0.30±0.16 nM 
vs 0.05±0.02 nM, p=0.0025) (table 3).
disCussiOn
While endocannabinoids receptors have been shown 
to be expressed in various tissues of the eye, this study 
investigated aqueous concentrations of endocanna-
binoids in individuals with or without diabetes. We 
observed differences in the aqueous concentrations 
among individuals undergoing routine cataract surgery 
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Figure 4 Ocular concentration of endocannabinoids (AEA, 
PEA, OEA and 2- AG) according to gender and diabetes 
status. 2- AG, 2- arachidonoylglycerol; AEA, anandamide; 
OEA, oleoylethanolamine; PEA, palmitoylethanolamine.
Table 3 Aqueous endocannabinoid concentrations by 
severity of retinopathy
2- AG AEA OEA PEA Sum
Female R0M0 Mean 0.05* 0.06 0.16 0.85 1.22
  SEM 0.02 0.02 0.05 0.14 0.25
Male R0M0 Mean 0.12 0.13 0.21 0.89 1.35
  SEM 0.05 0.06 0.07 0.20 0.35
Female DR Mean 0.30* 0.22 0.25 0.79 1.55
  SEM 0.16 0.14 0.14 0.31 0.72
Aqueous endocannabinoid levels grouped by both gender and 
level or diabetic retinopathy. Results were grouped by men and 
women with no diabetic retinopathy (male R0M0, female R0M0) 
and women with diabetic retinopathy (female DR). There were no 
men with diabetic retinopathy.
*Differences of 2- AG levels among women with no retinopathy 
compared with women with diabetic retinopathy showed 
significant difference at p=0.025.
AEA, anandamide; 2- AG, 2- arachidonoylglycerol; OEA, 
oleoylethanolamine; PEA, palmitoylethanolamine.
according to gender and diabetes status. In women 
without diabetes, higher levels of aqueous PEA and 
the sum of endocannabinoid were found compared 
with men without diabetes, and AEA was lower in 
women with diabetes compared with those without 
diabetes. The levels of AEA and OEA were lowest in 
women with diabetes with more significant retinopathy. 
When comparisons were made by severity of retinop-
athy, aqueous 2- AG levels were greatest in women with 
retinopathy, lower in men with no retinopathy and 
lowest in patients without diabetes. Diabetes status and 
ocular comorbidity suggested trends in lower aqueous 
levels of AEA. While the underlying cause and role 
of the differences in ocular concentration of these 
endocannabinoids remain speculative, we contend that 
this observation supports the need for further studies 
to investigate the potential role of ECS in the pathogen-
esis of diabetic retinopathy.
In the whole group, prior to gender stratification, 
we observed the aqueous concentration of 2- AG was 
slightly higher in patients with diabetes compared with 
those without diabetes, while the concentration of AEA 
was slightly lower in those with diabetes compared 
with those without diabetes, with PEA and OEA similar 
between patients with and without diabetes. A similar 
observation was noted when comparing those with and 
without ocular comorbidity. However, following gender 
stratification, the aqueous concentrations of AEA in 
women without diabetes were significantly higher 
than in both men and women without diabetes, with 
higher PEA and sum of endocannabinoid in women 
without diabetes compared with men without diabetes. 
Men without diabetes had the lowest values for each 
endocannabinoid, which were higher in men with 
diabetes. Our observation of the reduced aqueous AEA 
concentrations in diabetes is in contrast to a previous 
study which showed increased tissue levels of AEA in 
the retina, ciliary body and cornea.16 The reason for 
this is unclear, but the higher levels in women without 
diabetes may have produced this paradox and the 
gender of the samples was not specified. It is not known 
if non- steroidal anti- inflammatory drugs provided 
periprocedure may play some role in influencing the 
results as endocannabinoids are metabolised by cyclo- 
oxygenase 2 (COX-2).24 The ethanolamides AEA, OEA 
and PEA are hydrolysed by fatty acid amide hydro-
lase, which is inhibited by COX-2 inhibitors, and 2- AG 
is oxidised by COX-2 to active metabolites. COX-2 is 
increased in human diabetic and ischaemic retina as 
well as in retinal astrocytes of animal models of prolif-
erative retinopathy and in cell lines grown under 
hypoxic conditions.25 Prostanoids are angiogenic and 
induce VEGF- A, and COX-2 inhibition can reduce 
angiogenesis26; therefore, the use of nepafenac drops 
preoperatively may have had an influence on both 
proinflammatory and anti- inflammatory mediators. 
2- AG, which has a different metabolic pathway, was 
increased in more severe retinopathy in women, which 
compares with previous findings.16 A trial of nepafenac 
drops in patients without diabetes prior to cataract 
surgery would be informative.
Gender differences in circulating endocannabinoid have 
previously been reported.19 23 While the reason for gender 
differences seen in circulating endocannabinoid, and now 
in ocular endocannabinoid, is unknown, it is thought to 
be due to the interaction between sex hormones and the 
ECS. Previous studies have shown that oestrogen modu-
lates the endocannabinoid activity.27 28 Thus, future studies 
to determine the role of endocannabinoid- based therapy 
in modulating the pathogenesis of diabetic retinopathy 
should include gender stratification. Unfortunately, we did 
not have clinical information on the levels of sex hormones, 
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or any documentation of use of hormone replacement 
therapy or oral contraceptive pills.
The aetiological role of ECS in the pathogenesis of 
diabetic retinopathy is unclear. A previous study has 
reported the beneficial effects of CB
1
 receptor inhibi-
tion or genetic deletion27 in the development of diabetic 
retinopathy. In addition, CB
1
 receptor inhibition was 
shown to limit the vascular inflammation and cell 
death in a mouse model of diabetic retinopathy and in 
human retinal cell line exposed to high glucose,29 and 
attenuates hyperglycaemia- induced apoptosis in retinal 
pigment epithelial cells.30 Since diabetic nephropathy 
shares some pathogenic features of diabetic reti-
nopathy which characterised diabetic microvascular 
diseases, it is important to note that the CB
1
 receptor 
is overexpressed by renal podocytes in animal models 
in both type 1 and type 2 diabetes.31 32 In contrast to 
our observation in the present study, reduction of 
2- AG, which acts on both CB
1
 and CB
2
, was observed 
in the renal cortex from mice with early streptozotocin 
(STZ)- induced diabetes, and podocyte CB
2
 receptor 
expression is markedly downregulated in human 
biopsies from patients with advanced diabetic nephrop-
athy.33 These previous data on diabetic nephropathy 
indicate that the protective CB
2
 receptor signalling is 
impaired while the detrimental CB
1
 receptor signal-
ling is enhanced in diabetic microvascular diseases. It 
is likely that both hyperglycaemia and hypertension are 
important drivers of these changes since alterations as 
in cultured podocytes exposed to high glucose, were 
shown to increase CB
1
 receptor expression,34 while 
mechanical stress, mimicking glomerular capillary 
hypertension, downregulates CB
2
 receptors.33 35 By 
extrapolation, these differences may have an impact 
on the endocannabinoid ocular fluid concentration 
observed in the present study.
Some limitations to our study which may affect the 
interpretation of our study should be acknowledged. 
First, we do not have detailed metabolic and clinical 
parameters of study participants, such as haemoglobin 
A1c levels, 24- hour blood pressure levels, duration of 
diabetes, or concurrent glucose- lowering and blood 
pressure- lowering therapies. The latter is also rele-
vant since therapies which reduce activation of the 
renin angiotensin system have been shown to atten-
uate diabetic retinopathy progression.36 Furthermore, 
active maculopathy and proliferative retinopathy 
must be controlled prior to cataract surgery, and all 
patients with diabetic maculopathy, preproliferative or 
stable treated proliferative diabetic retinopathy were 
commenced on the anti- inflammatory nepafenac drops 
a day before surgery to reduce the risk of pseudophakic 
macular oedema. The potential effects of these 
routine presurgery protocols to reduce inflammation 
on the ocular concentration of endocannabinoid are 
not known. A further limitation is the relatively small 
number of patients and the unbalanced higher number 
of female patients, which limit our full interpretation of 
the observed ocular endocannabinoid levels as well as 
stratification of patients according to degree of diabetic 
retinopathy and gender status. Nonetheless, we believe 
that the current study adds to the available literature 
regarding the role of endocannabinoid fluid in the 
pathogenesis of diabetic retinopathy. While previous 
intervention studies with CB
1
 receptor antagonists have 
been performed in animal models of diabetic nephrop-
athy,31 34 37 we believe evidence derived from this study 
as well as from others should form a basis for future 
studies to investigate the effects of modulating the ECS 
in models of diabetic retinopathy.
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